Physiomics, a specialist in mathematical modelling, data science, and biostatistics, has announced that its Innovate UK-funded 'PREDICT-ONC' project has received both regulatory and ethical approval. This marks a significant step forward in the application of advanced analytics in medical research.
In another development, Cambridge Cognition has revealed that its 'CANTAB' cognitive assessment product is being used in two phase three clinical trials conducted by Bristol Myers Squibb for 'Cobenfy', a newly FDA-approved treatment for schizophrenia. This highlights the growing importance of cognitive assessment tools in the development of treatments for mental health conditions.
These advancements underscore the critical role of technology and data science in pushing the boundaries of medical research and treatment methodologies.
